Health Incubator Helsinki welcomes 9 promising health startups
Nine health and life sciences startups with great growth potential have joined the ranks of Health Incubator Helsinki, Finland’s unique health incubator program.
Health Incubator Helsinki is a long-term incubator program driving transformation of health innovation, research findings and expertise into international business, and attracting new talent and companies to Helsinki. The concept is unique in the Nordics in its focus and duration: the incubator focuses solely on health, and the program is up to three years long.
For its third incubator program that kickstarted in April 2022, Health Incubator Helsinki received in total 19 high-quality applications representing a wide range of health-related businesses. Majority of the applications came from Finland.
After interviews, nine startup companies/teams were selected for the program:
“During the selection process, we emphasised high growth potential, team dedication and high business scalability to international markets,” says Christian Lardot, Health Incubator Helsinki Leader.
“We look forward to working with the teams to support them with their growth plans,” says Lardot.
Up to 3 years of individually tailored coaching
The nine selected startups start their journey at Health Incubator Helsinki with a two-month onboarding program. The purpose is to provide all teams with the elementary information and sufficient knowledge so that they have a good starting point to start scaling up their businesses. The first months trainings cover topics such as how to get funding, team building, sales, creating the pitch deck, building the business and financial plan, investment strategy, regulatory issues, and intellectual property.
Health Incubator Helsinki provides an individual approach, offering up to three years of coaching and mentoring tailored for the needs of each startup. According to the startups already in the program, most valuable aspects are getting support in securing financing, peer support, contacts with investors and access to Helsinki Metropolitan health ecosystem.
The companies are provided with modern office and co-working facilities at Terkko Health Hub in Meilahti campus area, Helsinki, in close proximity of HUS Helsinki University Hospital. Apart from a minor fee for the office space the incubator services are free for the participants, and no equity is taken.
Health startups, be in touch!
“We would like to encourage interested startups and researchers to be in touch with us as we are continuously looking for new growth companies,” says Christian Lardot.
Health Incubator Helsinki started operations with the first batch of startups in 2020. It is a part of the continuum that supports startups and research-based teams from universities and SPARK Finland to develop their health and life sciences innovations and business concepts towards becoming growth companies. The incubator is a joint effort by the City of Helsinki and University of Helsinki, and it is provided in partnership with Health Capital Helsinki.
We encourage startups and researchers to be in contact with us as we are continuously looking for new growth companies.
Helsinki Partners
Meet the 2022 batch of Health Incubator Helsinki startups:
Corle is developing a small wireless medical device for the diagnostic and monitoring purposes of sleep apnea. The patented solution is a non-invasive optical sensor for continuous medical grade health data collection from the earlobe, sending the data via Bluetooth to a mobile phone application for analysis and sharing.
Fepod’s technology enables healthcare professionals to measure the real blood concentration of paracetamol, opioids and other pain medicine directly from a drop of blood at the point-of-care. The sampling process is fast & simple and the results are available in seconds. The required equipment consists of a mobile phone, an affordable & small potentiostat and mass-producible & disposable sensors.
The Karsa chemical analysis platform eliminates laborious workflows for the analysis of small molecules. The company wants to bring this approach to the IVD market with analysis of bodily fluids.
Lapsi Health is developing the new generation of digital biomarkers based on auscultatory sound. The data used as a biomarker has to be quantifiable and objective and the company’s novel technology greatly enhances its usage in medicine, relating it to the health-disease process for prognostic, diagnostic and therapeutic purposes.
Efficient lowering of blood cholesterol is pivotal in reducing the risk for heart attack and stroke, the most frequent causes of death globally. Different cholesterol-lowering drugs are available, but it is difficult to find an optimal treatment strategy for each person, resulting in suboptimal treatment and an increased risk for heart attack and stroke for many patients. The Moncyte analysis tool sheds light on why individuals respond differently to cholesterol-lowering medication. This will enable novel personalized treatment strategies, helping more patients to achieve their blood cholesterol target levels and reducing cardiovascular morbidity and mortality.
The biology and key role of NAD molecules in human metabolism has been well known for decades, but measuring them has been devilishly difficult. NADMED has now brought to market an accurate, fast, scalable, and well protected method to do just that. The assay enables research in large human cohorts, leading to a rapidly increasing number of clinical applications. NADMED already services clinical practitioners, researchers and drug development companies.
Olo empowers mindful exploration of self, community, and nature through personalized digital experiential learning that incorporates immersive listening and embodiment practice with real-time biofeedback and community support in a mobile app experience. Built on the foundation of neuroscience research and AI-powered technology, Olo’s app uniquely responds to the prolific mental health and stress management needs of each individual user.
Probiont
Probiont Oy is developing a personalized solution for cancer therapy efficacy assessment. The organ-on-a-chip platform is purposed to enable rapid screening of cancer immunotherapeutics, for early identification of effective treatment strategies for individual patients.
Sonai Health
Sonai Health develops a new solution for heart diagnosis, utilising patented sensor solution, cloud service and machine learning.
Contact information:
Christian Lardot
Health Incubator Helsinki Leader
Tel. +358 40 195 2639 christian.lardot@hel.fi
About Health Incubator Helsinki Health Incubator Helsinki is a comprehensive incubator program in Finland for research-based, early-stage teams and startups operating in the health sector. The incubator, initiated by the City of Helsinki and the University of Helsinki, and operating in close co-operation with Health Capital Helsinki, started operations in 2020. There are now 32 health startups participating in the incubator programs.
About Health Capital Helsinki Health Capital Helsinki is building the greatest health capital by developing the Helsinki Metropolitan health ecosystem, boosting the growth of innovation-driven startups and helping international investors and corporations find their opportunities and partners in Finland.
https://healthcapitalhelsinki.fi/wp-content/uploads/2024/10/Nayttokuva-2024-10-02-kello-17.44.10.jpg8202200Saana Lehtinenhttps://healthcapitalhelsinki.fi/wp-content/uploads/2020/02/hch_logo_horizontal_black-300x165-1.pngSaana Lehtinen2024-10-02 18:28:212024-10-03 11:34:03HUS Helsinki University Hospital recognised in the list of World’s Best Smart Hospitals 2025
We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
Essential website cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are necessary to deliver the website as intended, refusing them will have impact how our site functions. You can always block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will prompt you to accept or refuse cookies every time you revisit our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
Third party cookies
This website uses Twitter's and LinkedIn's cookies to help us improve our content and reach.
Please enable essential website cookies first so that we can save your preferences!
Privacy notice
You can read about how we use your data on our Privacy notice page.
https://healthcapitalhelsinki.fi/wp-content/uploads/2024/10/EsaDres-team-2024.jpg
1016
2200
Saana Lehtinen
https://healthcapitalhelsinki.fi/wp-content/uploads/2020/02/hch_logo_horizontal_black-300x165-1.png
Saana Lehtinen2024-11-21 08:03:222024-11-21 09:55:19EsaDres redefines wound care with tailored solutions
Newsweek
